Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HIP1701 vs HGP1809 (Vildagliptin) in Healthy Adults
NCT04087525Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax) of Vildagliptin at 24 hours and Area Under the Curve to the Last Measurable Concentration (AUClast) of Vildagliptin at 24 hours. Started Oct 2018; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04087525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04087525.